We conducted this scoping review to map and summarize scientific evidence on the role of clinical pharmacists in the palliative care of adults and elderly patients with cancer.
Data Sources
A literature search was performed in MEDLINE, PubMed Central, Embase, Web of Science, Scopus, and BVS/BIREME for studies published until November 22nd, 2020. Studies that reported work experiences adopted by clinical pharmacists in the palliative care of adults and elderly patients with cancer were included. Two independent authors performed study selection and data extraction. Any disagreements were resolved by discussion with the third and fourth authors. The pharmacist interventions identified in the included studies were described based on key domains in the DEPICT v.2.
Data Summary
A total of 586 records were identified, of which 14 studies fully met the eligibility criteria. Most of them were conducted in the United States of America (n = 5) and Canada (n = 5) and described the workplace of the pharmacist in clinic/ambulatory (n = 10). Clinical pharmacists performed several activities and provided services, highlighting medication review (n = 12), patient and caregivers education (n = 12), medication histories and-or medication reconciliation (n = 6). The pharmacist interventions were mostly conducted for patients/caregivers (n = 13), by one-on-one contact (n = 14), and by face-to-face (n = 13). Pharmacists were responsible mainly for change or suggestion for change in therapy (n = 12) and patient counselling (n = 12). Pharmacist interventions were well accepted by the clinical team. Overall, studies showed that pharmacists, within an interdisciplinary team, had significant impacts on measured outcomes.
Conclusions
In recent years, there have been advances in the role of the pharmacist in palliative care of patients with cancer and there are great opportunities in this field. They play an important role in managing cancer pain and other symptoms, as well as resolving drug related problems. We encourage more research to be carried out to strengthen this field and to benefit patients with advanced cancer with higher quality of life.
MaltaDCSilvaMMADMouraL,et al.The implantation of the surveillance system for Non-communicable diseases in Brazil, 2003 to 2015: successes and challenges. Rev Bras Epidemiol2017; 20: 661–675.
2.
World Health Organization. Noncommunicable diseases, https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (2021, accessed 26 April 2021).
3.
MarmotMBellR. Social determinants and non-communicable diseases: time for integrated action. Br Med J2019; 364: l251.
4.
World Health Organization. Global health estimates 2016: deaths by cause, Age, Sex, by country and by region, 2000–2016. Geneva: World Health Organization, 2018.
5.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. DOI: 10.3322/caac.21660. Epub ahead of print 4 Feb 2021.
6.
HowladerNNooneAMKrapchoM, et al.SEER Cancer statistics review, 1975–2017. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/ (based on November 2019 SEER data submission, posted to the SEER web site, April 2020; 2020, accessed 02 May 2021).
7.
FerrellBRTemelJSTeminS, et al.Integration of palliative care Into standard oncology care: american society of clinical oncology clinical practice guideline update. J Clin Oncol2017; 35: 96–112.
8.
FerrellBRTwaddleMLMelnickA,et al.National consensus project clinical practice guidelines for quality palliative care guidelines, 4th edition. J Palliat Med2018; 21: 1684–1689.
9.
CrawfordGBPriceSD. Team working: palliative care as a model of interdisciplinary practice. MJA2003; 179: S32–S34.
10.
O'ConnorMPughJJiwaM, et al.The palliative care interdisciplinary team: where is the community pharmacist?J Palliat Med2011; 14: 7–11.
11.
HerndonCMNeeDAtayeeRS, et al.ASHP Guidelines on the Pharmacist's Role in palliative and hospice care. Am J Health Syst Pharm2016; 73: 1351–1367.
12.
TriccoACLillieEZarinW, et al.PRISMA Extension for scoping reviews (PRISMAScR): checklist and explanation. Ann Intern Med2018; 169: 467–473.
13.
OuzzaniMHammadyHFedorowiczZ,et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev2016; 5: 210.
14.
RottaISalgadoTMFelixDC, et al.Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT. J Eval Clin Pract2015; 21: 584–590.
15.
BrueraEMichaudMViganoA, et al.Multidisciplinary symptom control clinic in a cancer center: a retrospective study. Support Care Cancer2001; 9: 162–168.
16.
StrasserFSweeneyCWilleyJ, et al.Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage2004; 27: 481–491.
17.
FairchildAPituskinERoseB, et al.The rapid access palliative radiotherapy program: blueprint for initiation of a one-stop multidisciplinary bone metastases clinic. Support Care Cancer2009; 17: 163–170.
18.
PituskinEFairchildADutkaJ, et al.Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study. Int J Radiat Oncol Biol Phys2010; 78: 527–532.
19.
GagnonLFairchildAPituskinE, et al.Optimizing pain relief in a specialized outpatient palliative radiotherapy clinic: contributions of a clinical pharmacistJ Oncol Pharm Pract2012; 18: 76–83.
20.
NogueiraTABarbosaLACalil-EliasS. Pharmaceutical home monitoring for oncology patients in palliative care. Lat Am J Pharm2012; 31: 772–776.
21.
EdwardsSJAbbottREdwardsJ, et al.Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract2014; 27: 46–52.
22.
CimminoKPisanoM. A Patient's Last wish at the End-of-life. Consult Pharm2016; 31: 375–380.
23.
DiScalaSLOnofrioSMillerM, et al.Integration of a clinical pharmacist into an interdisciplinary palliative care outpatient clinic. Am J Hosp Palliat Care2017; 34: 814–819.
24.
YamadaMMatsumuraCJimaruY, et al.Effect of continuous pharmacist interventions on pain control and Side effect management in outpatients with cancer receiving opioid treatments. Biol Pharm Bull2018; 41: 858–863.
25.
DuffyAPBembenNMLiJ,et al.Facilitating home hospice transitions of care in oncology: evaluation of clinical Pharmacists’ interventions, hospice program satisfaction, and patient representation rates. Am J Hosp Palliat Care2018; 35: 1181–1187.
26.
GeumMJAhnJHKimJS, et al.Interprofessional collaboration between a multidisciplinary palliative care team and the team pharmacist on pain management. Am J Hosp Palliat Care2019; 36: 616–622.
27.
EdwardsZBennettMIBlenkinsoppA. A community pharmacist medicines optimisation service for patients with advanced cancer pain: a proof of concept study. Int J Clin Pharm2019; 41: 700–710.
28.
PatelJNBoselliDHamadehIS, et al.Pain management using clinical pharmacy assessments With and without pharmacogenomics in an oncology palliative medicine clinic. JCO Oncol Pract2020; 16: e166–e174.
29.
VisacriMBTavaresMGBarbosaCR, et al.Clinical pharmacy in onco-hematology and bone marrow transplant: a valuable contribution to improving patient safety. J Oncol Pharm Pract2021; 27: 1172–1180.
30.
VisacriMBda PenhaNSBarrosMA, et al.Clinical pharmacy services in pediatric hematology-oncology: a real need. J Oncol Pharm Pract2020; 26: 2066–2068.
31.
VisacriMBDuarteNCLimaTM, et al.Adverse reactions and adherence to capecitabine: a prospective study in patients with gastrointestinal cancer. J Oncol Pharm Pract 2021: 1–11. DOI: 10.1177/1078155221989420. Epub ahead of print 20 Jan 2021.
32.
The EQUATOR Network. Enhancing the QUAlity and Transparency Of health Research, https://www.equator-network.org/ (accessed 09 August 2021).
33.
van MilJWWesterlundLOHersbergerKE,et al.Drug-related problem classification systems. Ann Pharmacother2004; 38: 859–867.
34.
PkAAdepuR. Drug related problems: an over view of various classification systems. Asian J Pharm Clin Res2014; 7: 7–10.
35.
BasgerBJMolesRJChenTF. Application of drug-related problem (DRP) classification systems: a review of the literature. Eur J Clin Pharmacol2014; 70: 799–815.
36.
FainsingerRNekolaichukCLawlorP, et al.A multicentre validation study of the revised edmonton staging system for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage2005; 29: 224–237.
37.
SwarmRAPaiceJAAnghelescuDL, et al.Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw2019; 17: 977–1007.
38.
FallonMGiustiRAielliF, et al.Management of cancer pain in adult patients: eSMO clinical practice guidelines. Ann Oncol2018; 29: iv166–iv191.
KnotkovaHFinePGPortenoyRK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage2009; 38: 426–439.
41.
Owusu-ObengAWeitzelKWHattonRC, et al.Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy2014; 34: 1102–1112.
42.
GraczykMBorkowskaAKrajnikM. Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain. Pol Arch Intern Med2018; 128: 89–97.
43.
BrueraEKuehnNMillerMJ, et al.The edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care1991; 7: 6–9.
44.
National Cancer Comprehensive Network. NCCN Guidelines, Supportive Care, https://www.nccn.org/guidelines/category_3 (2021, accessed 26 September 2021).
45.
FernandesBDAlmeidaPHRFFoppaAA, et al.Pharmacist-led medication reconciliation at patient discharge: a scoping review. Res Social Adm Pharm2020; 16: 605–613.
46.
AntonioAPNSilvaMBFCSouzaMFR,et al.Deprescription in oncological palliative care: an integrating review. Rev Bras Farm Hosp Serv Saude2019; 10: 0412.
47.
SuzukiSUchidaMSugaY, et al.A nationwide survey of community pharmacist contributions to polypharmacy in opioid-using and Non-using cancer patients in Japan. Biol Pharm Bull2019; 42: 1164–1171.
48.
UchidaMSuzukiSSugawaraH, et al.A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan. J Pharm Health Care Sci2019; 5: 14.
49.
Deprescribing.org. https://deprescribing.org/ (2021, accessed 26 September 2021).
50.
Primary Health Tasmania. https://www.primaryhealthtas.com.au/for-health-professionals/programs/managing-medicines/ (2021, accessed 26 September 2021).
51.
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication Use in older adults. J Am Geriatr Soc2019; 67: 674–694.
52.
GallagherPO’MahonyD. STOPP (Screening tool of older Persons’ potentially inappropriate prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing2008; 37: 673–679.
53.
O’MahonyDO'SullivanD, et al.STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing2015; 44: 213–218.
54.
Renom-GuiterasAMeyerGThürmannPA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven european countries. Eur J Clin Pharmacol2015; 71: 861–875.
55.
HoltSSchmiedlSThürmannPA. Potentially inappropriate medications in the elderly: the PRISCUS listDtsch Arztebl Int2010; 107: 543–551.
56.
HussainySYBeattieJNationRL, et al.Palliative care for patients with cancer: what are the educational needs of community pharmacists?Support Care Cancer2006; 14: 177–184.
57.
PruskowskiJPatelRBrazeauG. The need for palliative care in pharmacy education. Am J Pharm Educ2019; 83: 7410.
58.
XueYSchulman-GreenDCzaplinskiC, et al.Pain attitudes and knowledge among RNs, pharmacists, and physicians on an inpatient oncology service. Clin J Oncol Nurs2007; 11: 687–695.
59.
UchidaMHadaMYamadaM, et al.Impact of a systematic education model for palliative care in cancer. Pharmazie2019; 74: 499–504.
60.
HerndonCMStrasselsSAStricklandJM, et al.Consensus recommendations from the strategic planning summit for pain and palliative care pharmacy practice. J Pain Symptom Manage2012; 43: 925–44.e1–10.
61.
BarnettGMannRE. Empathy deficits and sexual offending: a model of obstacles to empathy. Aggression and violent behavior. Aggress Violent Behav2013; 18: 228–239.
62.
SinclairSBeamerKHackTF, et al.Sympathy, empathy, and compassion: a grounded theory study of palliative care patients’ understandings, experiences, and preferences. Palliat Med2017; 31: 437–447.
63.
Accreditation council for pharmacy education. https://www.acpe-accredit.org (2021, Accessed 09 October 2021).
64.
HobeikaEHallitSSacreH, et al.Factors associated with empathy among community pharmacists in Lebanon. J Pharm Policy Pract2020; 13: 32.
65.
LonieJM. From counting and pouring to caring: the empathic developmental process of community pharmacists. Res Social Adm Pharm2006; 2: 439–457.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
